Fighting obesity with Ozempic could cut national debt: GOP Rep.
- Rep. David Schweikert says obesity costs America trillions a year
- Helping people lose weight can put this money back into economy, he says
- Schweikert wants to see drugs used for weight loss become more accessible
ovp test
Male shot by female at Shreveport apartment
Class to create biodiverse backyard
Rules for outbursts at Caddo School Board Meeting
maylen
(NewsNation) — Could helping fight obesity make a difference in reducing the national deficit?
One GOP congressman, Rep. David Schweikert of Arizona, says it could — so he wants to see drugs that help people lose weight become more accessible.
Ozempic, Wegovy and other “GLP-1 receptor agonists,” as they are called, have exploded in popularity in the United States. While Ozempic, perhaps the most popular, was created to help those with Type 2 diabetes lower their blood sugar, some doctors have prescribed it off-label to assist in weight loss. Medical experts, though, have warned against using these drugs for what they’re prescribed for.
The argument Schweikert has been making is that the Joint Economic Committee expects the U.S. to spend trillions of dollars on treating obesity-related illnesses such as heart attack, stroke, diabetes and even certain forms of cancer.
By curbing obesity, he says, the U.S. could use this money to make meaningful cuts to its debt and deficit over the next 10 years.
Best Prime Day Deals for 2024:
— Products still on sale after Prime Big Deal Days
— Beats headphones and tablets remain marked down
— Make sure you’re stocked with Apple products
BestReviews is reader-supported and may earn an affiliate commission.
In addition, helping people shed the pounds can help put money back into the economy, Schweikert argues. Business Insider, for example, reports that airlines are saying they could save money on fuel with lighter passengers.
However, Schweikert told NewsNation’s Joe Khalil in an interview that it has been hard to attempt to tackle this issue because there’s such a stigma around obesity. While Schweiker acknowledges that what he’s saying could offend those who struggle with the condition, he insists we have to get past that.
“Once you actually start to see the potential positives here, the hell with the theater of people’s feelings,” Schweikert said. “In some ways, it’s ‘We love, we care, and we’re gonna try to make people’s lives better.'”
